Alkermes (NASDAQ:ALKS) updated its FY17 earnings guidance on Wednesday. The company provided EPS guidance of $0.03-0.22 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.12. The company issued revenue guidance of $870-900 million, compared to the consensus revenue estimate of $882.79 million.
A number of analysts recently commented on the stock. Barclays set a $50.00 price objective on shares of Alkermes and gave the company a hold rating in a research report on Thursday, October 26th. ValuEngine cut shares of Alkermes from a hold rating to a sell rating in a research report on Monday, October 23rd. JPMorgan Chase & Co. set a $78.00 price objective on shares of Alkermes and gave the company a buy rating in a research report on Friday, October 27th. BidaskClub upgraded shares of Alkermes from a sell rating to a hold rating in a research report on Wednesday, December 27th. Finally, Citigroup set a $62.00 price objective on shares of Alkermes and gave the company a hold rating in a research report on Thursday, October 26th. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has an average rating of Hold and an average price target of $63.33.
Alkermes (NASDAQ:ALKS) opened at $58.71 on Thursday. Alkermes has a one year low of $46.42 and a one year high of $63.40. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05. The company has a market cap of $9,030.00, a PE ratio of -52.89 and a beta of 2.13.
Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.04. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. The company had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. During the same period in the prior year, the business posted ($0.09) EPS. The company’s quarterly revenue was up 20.6% on a year-over-year basis. research analysts anticipate that Alkermes will post -0.59 earnings per share for the current year.
In other Alkermes news, Director Richard F. Pops sold 50,000 shares of the stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $48.87, for a total value of $2,443,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Michael J. Landine sold 15,000 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $48.71, for a total transaction of $730,650.00. Following the completion of the transaction, the senior vice president now directly owns 178,693 shares in the company, valued at $8,704,136.03. The disclosure for this sale can be found here. Insiders sold a total of 136,417 shares of company stock valued at $7,259,391 over the last quarter. 5.34% of the stock is currently owned by company insiders.
WARNING: “Alkermes (ALKS) Issues FY17 Earnings Guidance” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/alkermes-alks-issues-fy17-earnings-guidance.html.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.